Halozyme Announces FDA Approval of Roche's Tecentriq …
WEB2 days ago · FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced ...
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing
WEB4 days ago · September 11, 2024 at 11:45 AM EDT. Save. Roche Holding AGsaid side effects in a highly anticipated study of its experimental obesity pill were milder when it eased patients into higher doses more ...
Halozyme Announces FDA Approval of Roche's Subcutaneous …
WEB1 day ago · Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading ...
Roche opens Pharma Research and Development Center in Basel …
WEB5 days ago · Switzerland’s most innovative research and development center underscores Roche’s long-term investment in scientific advancement to meet patient needsThe new center will simplify and increase ...
How Roche passed on a potential $14bn-a-year weight-loss pill
WEBAug 15, 2024 · Swiss drugmaker Roche turned down a potential $14bn-a-year weight-loss pill now being developed by rival Eli Lilly that could have given it a leading position in the booming weight-loss...
Roche to accelerate Wegovy weight loss rivals after positive trials
WEBJul 29, 2024 · Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company’s two obesity drug ...
Roche announces FDA approval of one of the ... - Roche …
WEBBASEL, May 15, 2024 — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution, one of the first available in the United States.
FDA grants Breakthrough Therapy Designation to Roche’s …
WEBBasel, 21 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an...
Roche agrees $7.1bn deal for Telavant to boost drug pipeline
WEBOct 23, 2023 · Roche plans to buy immunology company Telavant from Roivant Sciences and Pfizer for more than $7bn, as the drugmaker’s new chief executive seeks to replenish its drug pipeline.
Roche announces U.S. collaboration with Pfizer to help patients …
WEBRoche today announced it has entered into a U.S.-focused collaboration with Pfizer to drive awareness and educate on the importance of timely COVID-19 testing, available treatment options, symptoms and the high-risk factors that can …
- Some results have been removed